Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19
Sarah C J Jorgensen, Razieh Kebriaei, Linda Dresser
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2020) Vol. 40, Iss. 7, pp. 659-671
Open Access | Times Cited: 240

Showing 1-25 of 240 citing articles:

Remdesivir against COVID-19 and Other Viral Diseases
Jakob J Malin, Isabelle Suárez, Vanessa Priesner, et al.
Clinical Microbiology Reviews (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 260
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
Brian T. Garibaldi, Kunbo Wang, Matthew L. Robinson, et al.
JAMA Network Open (2021) Vol. 4, Iss. 3, pp. e213071-e213071
Open Access | Times Cited: 149
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
Robert J. Geraghty, Matthew T. Aliota, Laurent Bonnac
Viruses (2021) Vol. 13, Iss. 4, pp. 667-667
Open Access | Times Cited: 140
Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse
Frauke Seehusen, Jordan J. Clark, Parul Sharma, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 1020-1020
Open Access | Times Cited: 93
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase
Jian‐Yuan Zhao, Saisai Guo, Dongrong Yi, et al.
Antiviral Research (2021) Vol. 190, pp. 105078-105078
Open Access | Times Cited: 81
Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature
Joseph Clinton, Sara Kiparizoska, Soorya Aggarwal, et al.
Drug Safety (2021) Vol. 44, Iss. 11, pp. 1125-1149
Open Access | Times Cited: 65
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
Subrata Deb, Anthony Allen Reeves, Robert Hopefl, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 655-655
Open Access | Times Cited: 64
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jialing Yin, Chengcheng Li, Chunhong Ye, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 824-837
Open Access | Times Cited: 64
Consequences of COVID-19 for the Pancreas
Urszula Abramczyk, Maciej Nowaczyński, Adam Słomczyński, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 864-864
Open Access | Times Cited: 52
Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era
Li Guo, Hui Yao, Weikai Chen, et al.
Horticulture Research (2022) Vol. 9
Open Access | Times Cited: 38
Antiviral fibrils of self-assembled peptides with tunable compositions
Joseph Dodd‐o, Abhishek Roy, Zain Siddiqui, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications
Jaykaran Charan, Rimple Jeet Kaur, Pankaj Bhardwaj, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 14, Iss. 1, pp. 95-103
Open Access | Times Cited: 66
Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?
Natasha N. Pettit, Jennifer Pisano, Cynthia T. Nguyen, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e3990-e3995
Open Access | Times Cited: 64
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database
Alexandre O. Gérard, Audrey Laurain, Audrey Fresse, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 4, pp. 1021-1024
Closed Access | Times Cited: 62
COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks
Markus Blaess, Lars Kaiser, Martin Sauer, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 4953-4953
Open Access | Times Cited: 53
Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice
Wen-juan Hu, Lu Chang, Ying Yang, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 7, pp. 1195-1200
Open Access | Times Cited: 53
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
Daniela Krentz, Katharina Zenger, Martin Alberer, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2228-2228
Open Access | Times Cited: 51
Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019
Mohamed Fizur Nagoor Meeran, Hayate Javed, Charu Sharma, et al.
Heliyon (2021) Vol. 7, Iss. 2, pp. e05990-e05990
Open Access | Times Cited: 48
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
Ágnes Telbisz, Csilla Temesszentandrási‐Ambrus, Orsolya Mózner, et al.
Pharmaceutics (2021) Vol. 13, Iss. 1, pp. 81-81
Open Access | Times Cited: 44
Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study
Emilio Attena, Stefano Albani, Alberto Enrico Maraolo, et al.
Circulation Arrhythmia and Electrophysiology (2021) Vol. 14, Iss. 7
Open Access | Times Cited: 42
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
Iart Luca Shytaj, Mohamed Fares, Lara Gallucci, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 35
Current Effective Therapeutics in Management of COVID-19
Kavya Atluri, Iris Aimlin, Shitij Arora
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3838-3838
Open Access | Times Cited: 31
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study
Carlos King Ho Wong, Ivan Chi Ho Au, Wing Yiu Cheng, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 1, pp. 121-130
Open Access | Times Cited: 29
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112700-112700
Open Access | Times Cited: 27
In silico Evaluation of Bisphosphonates Identifies Leading candidates for SARS-CoV-2 RdRp inhibition
Muzaffar-Ur-Rehman Mohammed, Kishor Suryakant Chougule, Ala Chandu, et al.
Journal of Molecular Graphics and Modelling (2025) Vol. 136, pp. 108939-108939
Closed Access
Page 1 - Next Page

Scroll to top